Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 12/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936775 | 0.85 | SCN5A (0.77) | SCN5ACYP1A2SCN1ASCN2AALOX5AP | |
| SCHEMBL937674 | 0.79 | SCN5A (0.59) | SCN5ACYP1A2SCN1ASCN2AMAPK14 | |
| SCHEMBL20203803 | 0.73 | CYP1A2 (0.60) | SCN5ACYP1A2SCN1ASCN2AMAPK14 | |
| SCHEMBL12909253 | 0.73 | SCN5A (0.77) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL938156 | 0.72 | SCN5A (0.64) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL936867 | 0.72 | SCN5A (1.00) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL19056332 | 0.72 | SCN5A (0.75) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL938669 | 0.72 | SCN5A (0.75) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL936567 | 0.72 | SCN5A (0.69) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL937586 | 0.72 | SCN5A (0.55) | SCN5ACYP1A2SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885CYP1A2 1580/4885SCN1A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.